Slc1A1 Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
| Attribute | Value | [1]
|-----------|-------|
| Protein Name | Sodium/Glutamate Transporter 1 |
| Gene Symbol | SLC1A1 |
| UniProt ID | P43005 |
| NCBI Gene ID | 6507 |
| Protein Family | SLC1 family (EAAT) |
| Molecular Weight | ~57 kDa |
| Subcellular Location | Plasma membrane |
| Expression | Brain, kidney, intestine |
SLC1A1 (Sodium/Glutamate Transporter 1), also known as EAAT3 (Excitatory Amino Acid Transporter 3), is a high-affinity glutamate transporter responsible for clearing excitatory neurotransmitters from the synaptic cleft. This protein plays crucial roles in preventing excitotoxicity and maintaining glutamate homeostasis in the brain.
SLC1A3 (EAAT1) represents a promising therapeutic target for multiple neurological conditions. The transporter's role in glutamate homeostasis makes it an attractive target for modulating excitotoxicity.
| Approach | Mechanism | Disease | Status |
|----------|-----------|---------||
| EAAT1 agonists | Increase uptake | Epilepsy | Preclinical |
| EAAT1 modulators | Allosteric modulation | Migraine | Research |
| Gene therapy | Increase expression | AD | Experimental |
Transport across the BBB remains a challenge for EAAT1-targeted drugs. Novel delivery approaches include:
EAAT1 expression patterns may serve as biomarkers for:
Several SNPs in SLC1A3 have been associated with:
The study of Slc1A1 Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Arnold PD, Sicard T, Burroughs E, et al. Glutamate system genes associated with OCD. Arch Gen Psychiatry. 2008. ↩︎